Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression

Area of Science:

• Neuroscience
• Molecular Biology
• Genetics

Background:

• Gain-of-function mutations in leucine-rich repeat kinase 2 (LRRK2) are linked to Parkinson's disease.
• The precise molecular mechanisms underlying LRRK2 pathogenesis remain unclear.
• LRRK2's role in regulating protein synthesis and its interaction with microRNAs (miRNAs) are not well understood.

Purpose of the Study:

• To investigate the molecular mechanism of LRRK2 in Parkinson's disease pathogenesis.
• To determine if LRRK2 interacts with the miRNA pathway to regulate protein synthesis.
• To explore potential miRNA-based therapeutic strategies for LRRK2-associated Parkinson's disease.

Main Methods:

• Utilized Drosophila models to study LRRK2 interactions with miRNAs (let-7 and miR-184*) and their targets (e2f1 and dp mRNAs).
• Manipulated miRNA levels and target responsiveness to assess effects on LRRK2 pathogenesis.
• Examined LRRK2 association with components of the RNA-induced silencing complex (RISC), including Argonaute proteins (dAgo1, hAgo2).

Main Results:

• Pathogenic LRRK2 antagonizes let-7 and miR-184*, causing E2F1/DP overproduction, which is critical for pathogenesis.
• Genetic or pharmacological disruption of let-7 or miR-184* function mimicked LRRK2 toxicity.
• Increasing let-7 or miR-184* levels ameliorated LRRK2-induced pathogenic effects.
• LRRK2 interacts with dAgo1 and hAgo2, negatively regulates dAgo1 levels in aged fly brains, and promotes phospho-4E-BP1 association with hAgo2.

Conclusions:

• Impaired miRNA pathway function and subsequent deregulated E2F1/DP synthesis are key events in LRRK2 pathogenesis.
• LRRK2's interaction with the miRNA pathway and RISC is crucial for its neurotoxic effects.
• These findings suggest novel miRNA-based therapeutic avenues for LRRK2-associated Parkinson's disease.